Clinical Trials Logo

Filter by:
NCT ID: NCT06315101 Completed - Clinical trials for Unresectable Hepatocellular Carcinoma

Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China

Start date: September 1, 2023
Phase:
Study type: Observational

This study aims to assess the effectiveness and safety of lenvatinib plus Chinese Herbal Medicine (CHM) for patients with uHCC in China.

NCT ID: NCT06314958 Recruiting - Colorectal Cancer Clinical Trials

Stage II/III Colorectal Cancer Recurrence

CENSURE
Start date: March 15, 2023
Phase:
Study type: Observational

This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation.

NCT ID: NCT06314906 Recruiting - Nausea and Vomiting Clinical Trials

Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer

Start date: March 7, 2024
Phase: Phase 3
Study type: Interventional

This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment.

NCT ID: NCT06314880 Recruiting - Healthy Volunteers Clinical Trials

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

Start date: July 22, 2023
Phase: Phase 1
Study type: Interventional

The research objective is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity.

NCT ID: NCT06314867 Active, not recruiting - Healthy Volunteers Clinical Trials

Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23

Start date: January 30, 2023
Phase: Phase 3
Study type: Interventional

The research objective is to evaluate lot-to-lot consistency and immune persistence of three commercial batches of 23 valent pneumococcal polysaccharide vaccine.

NCT ID: NCT06314685 Active, not recruiting - Healthy Population Clinical Trials

Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years

Start date: December 10, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 months to 5 years old.

NCT ID: NCT06314659 Active, not recruiting - Healthy Population Clinical Trials

Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months

Start date: September 17, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the immunogenicity and safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 to 5 months old.

NCT ID: NCT06314594 Recruiting - Clinical trials for Adolescent Scoliosis

the Individualized Stepwise Treatment Mode of Adolescent Idiopathic Scoliosis

Start date: December 20, 2023
Phase: N/A
Study type: Interventional

Based on the risk factors affecting adolescent scoliosis found in the previous social survey, this project adopts the paradigm based on transfer learning and semi-supervised learning, and uses mathematical methods such as multiple learning methods and Transformer image classification algorithms to develop and verify the early warning model and stepped treatment model of adolescent scoliosis, and conducts cost-effect analysis.

NCT ID: NCT06314542 Recruiting - Lung Cancer Clinical Trials

Quantitative Evaluation of the Impact of Relaxing Eligibility Criteria for Lung Cancer Based on Real-world Data

Start date: January 1, 2013
Phase:
Study type: Observational

Eligibility criteria for cancer drug trials are generally too stringent, leading to key issues such as low enrolment rates and lack of population diversity. In order to evaluate the REC of NSCLC drug trials, this study will use deep learning methods to construct a structured real-world database of NSCLC across dimensions, and quantitatively assess the independent contribution of changes in each eligibility criterion to patient numbers, clinical efficacy and safety.

NCT ID: NCT06314529 Recruiting - Thalassemia, Beta Clinical Trials

Long-term Follow-up Study of BHC001 for TDT

Start date: December 14, 2022
Phase:
Study type: Observational

Observe long-term safety risk and long-term efficacy after intravenous infusion of BHC001 in TDT subjects.